How to Buy Alnylam Pharmaceuticals Stock
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Alnylam Pharmaceuticals stock last closed at $232.75, down 0.77% from the previous day, and has increased 59.65% in one year. It has overperformed other stocks in the Biotechnology industry by 1.37 percentage points. Alnylam Pharmaceuticals stock is currently +63.94% from its 52-week low of $141.98, and -23.54% from its 52-week high of $304.39.
As of Apr 21, 2025, there are 129.46M ALNY shares outstanding. The market cap of ALNY is $30.13B. In the last 24 hours, 796,121 ALNY shares were traded.
How to Buy Alnylam Pharmaceuticals Stock
Wondering how to invest in Alnylam Pharmaceuticals stock? Here's how.
- Decide where to buy Alnylam Pharmaceuticals stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Alnylam Pharmaceuticals stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit money your brokerage account: Choose your method of payment and add your info.
- Evaluate Alnylam Pharmaceuticals stock: The Alnylam Pharmaceuticals ticker symbol is ALNY. Is Alnylam Pharmaceuticals stock a good investment? Should you buy shares of ALNY? How do ALNY's underlying business fundamentals look? Do top analysts think Alnylam Pharmaceuticals is a good buy? Why has ALNY's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if ALNY is a good stock to buy).
- Execute your ALNY purchase: Decide if you will purchase ALNY shares at the current market price or use a limit order to purchase ALNY shares at a particular price.
- Keep tabs on your ALNY investment: Create a watchlist to get the latest news on your new investment in Alnylam Pharmaceuticals shares.
Step 1: Decide where to buy Alnylam Pharmaceuticals stock
You will need an online brokerage account in order to access the NASDAQ market and buy ALNY stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you can invest in ALNY today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to start a new trading account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have finished signing up on the best stock trading app for beginners, you can securely and quickly fund your account:
Watch the tutorial below if you need help depositing funds into your new investment account.
Step 4: Evaluate Alnylam Pharmaceuticals stock
Once you have selected the best place to buy Alnylam Pharmaceuticals stock, it's crucial to analyze their stock prior to investing, so you can comprehend the risk as well as the upside.
Alnylam Pharmaceuticals shares data
Fundamentals of ALNY
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on ALNY's stock page.
Is ALNY stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ALNY's intrinsic value.
Using relative valuations measures:
- ALNY may be overvalued based on its P/B ratio of 449.13x, relative to Biotechnology industry P/B ratio of 4.04x
You can do additional valuation analysis on ALNY's stock here.
ALNY Financial Health Summary
Passed Financial Due Diligence Checks:
- ALNY has cash burn of 42589000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the ALNY balance sheet.
- There are more short-term assets than long-term liabilities on the ALNY balance sheet.
- ALNY profit margin has gone up from -24.1% to -12.4% in the past year.
- ALNY has $2.69B in cash and short term investments. This is enough to cover its annual cash burn of $42.59M.
Failed Financial Due Diligence Checks:
- Total ALNY debt is higher than 5 years ago, relative to shareholder equity.
- ALNY has a relatively high debt to equity ratio of 62.2.
Do Wall Street analysts think it's a good time to buy Alnylam Pharmaceuticals stock
Out of 17 Wall Street analysts who give ratings on ALNY, the consensus analyst rating on ALNY is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent ALNY Analyst Recommendations
Paul Matteis, a bottom 5% analyst from Stifel Nicolaus maintains ALNY with a strong buy rating and raises their ALNY price target from $300.00 to $345.00, on Mar 31, 2025.
Jessica Fye, a top 6% analyst from JP Morgan upgrades ALNY to a strong buy rating and raises their ALNY price target from $280.00 to $328.00, on Mar 24, 2025.
JP Morgan's Jessica Fye upgraded their rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Hold to Strong Buy on 2025/03/24. The analyst also raised their price target by 17.1% from $280 to $328.
Following an assessment of JP Morgan's "positive results" from checks with thirty cardiologists, Fye said they raised their TTR silencer predictions to account for a bigger total market potential in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Comments from doctors have shown that there is room for significant expansion among those with ATTR-CM diagnoses, the analyst added.
According to Fye, the poll also showed positive reviews of new ATTR-CM product penetration, which is predicted to increase by 300% in the coming five years.
In conclusion, the analyst predicted a bigger ATTR-CM market as well as increased sales for Alnylam Pharmaceuticals' Amvuttra in the future.
Footnotes
ATTR-CM is a rare and potentially fatal heart condition caused by the buildup of amyloid fibrils in the heart muscle.
David Lebovitz, a bottom 10% analyst from Citigroup maintains ALNY with a strong buy rating and raises their ALNY price target from $338.00 to $351.00, on Mar 21, 2025.
Whitney Ijem, a bottom 10% analyst from Canaccord Genuity maintains ALNY with a strong buy rating and raises their ALNY price target from $385.00 to $390.00, on Mar 21, 2025.
Luca Issi, a bottom 3% analyst from RBC Capital maintains ALNY with a buy rating and raises their ALNY price target from $310.00 to $330.00, on Mar 21, 2025.
You can dive deeper into what analysts are forecasting on the Alnylam Pharmaceuticals stock forecast page.
ALNY Trading Indicators
ALNY Performance Metrics
Last year, ALNY revenue was $2.25B. Over the last 5 year, ALNY's revenue has increased by 59.21% per year. This was faster than the Biotechnology industry average of 44.31%.
You can analyze ALNY's earnings and revenue performance here.
Latest Insiders Trades at ALNY
In the last year, insiders at ALNY have sold more shares than they have bought.
Pushkal Garg, CMO EVP Dev Med Affairs of ALNY, was the latest ALNY insider to buy. They bought $229,887.90 worth of ALNY shares on Mar 24, 2025.
Research more about who owns ALNY shares here.
Can I get consistent income from ALNY stock?
No, Alnylam Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about ALNY
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your ALNY purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually sufficient. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount, use a limit order.
Press the Open Trade button and your broker will execute the order.
If you want additional assistance investing in stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your ALNY investment
Now that you own some ALNY stock, you'll want to keep up with your new shares.
Put ALNY on a watchlist to keep track of your ALNY stock.
ALNY Feed
How to Buy Stock in Alnylam Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Alnylam Pharmaceuticals stock right now:
- Decide where to buy Alnylam Pharmaceuticals stock
- Sign up for a brokerage account
- Deposit money your brokerage account
- Evaluate Alnylam Pharmaceuticals stock
- Execute your ALNY purchase
- Keep tabs on your ALNY investment
If you require a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your investment in Alnylam Pharmaceuticals, add ALNY to your watchlist by clicking the button below.
More "How To" Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.